Further Exploration of β-Carboline Antimalarials and Preliminary Study of Quinazoline Analogs

Malaria, caused by an infection from a protozoan parasite of the genus Plasmodium, continues to be a deadly disease. In 2021, the disease caused an estimated 619,000 deaths. Due to the emergence of resistance to available antimalarial drugs, there is a constant need for newer antimalarials. The Carlier group had reported the discovery of β-carboline carboxamide PRC1584, which showed good growth inhibition of asexual blood stage (ABS) P. falciparum, low general cytotoxicity, good oral bioavailability and efficacy (4 x 40 mg/kg/day) in a P. berghei mouse model of malaria. This study deals with the exploration of further synthesized β-carboline compounds and also potency of quinazoline analogs of PRC1584 as well.